Tyra Biosciences’ (TYRA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research report report published on Monday,Benzinga reports. The firm currently has a $30.00 target price on the stock.

Other research analysts also recently issued reports about the company. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Stock Down 0.8 %

TYRA opened at $8.65 on Monday. The firm has a market cap of $437.72 million, a P/E ratio of -5.37 and a beta of 1.09. The business’s fifty day simple moving average is $12.04 and its 200 day simple moving average is $16.08. Tyra Biosciences has a 52 week low of $8.40 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. As a group, equities analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the sale, the director now owns 443,885 shares of the company’s stock, valued at approximately $6,107,857.60. This represents a 1.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 21,998 shares of company stock worth $344,818. 15.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors have recently bought and sold shares of TYRA. KLP Kapitalforvaltning AS acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at $31,000. US Bancorp DE acquired a new position in shares of Tyra Biosciences during the fourth quarter worth about $50,000. BNP Paribas Financial Markets purchased a new stake in shares of Tyra Biosciences in the fourth quarter worth about $60,000. Aquatic Capital Management LLC acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $64,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock valued at $132,000 after buying an additional 3,236 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.